Selective PARP1 Inhibitors for Lower-Toxicity Brain Tumor Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current PARP inhibitors, including PARP1/2 inhibitors, exhibit significant side effects on the blood and gastrointestinal tract, limiting their clinical application and patient safety.
Innovation Solution
Development of selective PARP1 inhibitors with high specificity and lower toxicity, capable of penetrating the blood-brain barrier, offering improved efficacy for treating brain tumors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PARP1/2 inhibitors are used for cancer treatment, then anti-tumor efficacy is improved, but side effects on blood and gastrointestinal tract increase
Solution Approach 1:
The patent segments the PARP enzyme family inhibition by designing compounds that selectively inhibit PARP1 while sparing PARP2. This is achieved through specific molecular structure modifications in formulas (I-A), (I), (II), and (III) that create steric hindrance or electronic effects preventing PARP2 binding while maintaining PARP1 inhibition, thereby reducing off-target side effects on blood and gastrointestinal tract
Solution Approach 2:
The patent applies local quality by introducing specific substituent groups at particular positions in the molecular structure (R1, R0, RX, R2a-R2f groups in the formulas) that locally modify the compound's interaction with the PARP1 active site. These localized structural features enhance binding affinity and selectivity for PARP1 over PARP2, improving therapeutic index by reducing systemic toxicity
2Object-affected harmful factors
If selective PARP1 inhibitors are developed, then toxicity is reduced, but compound structure complexity increases
Solution Approach 1:
The patent utilizes parameter changes by systematically varying substituent parameters (R1 from C1-6 alkyl to C3-8 cycloalkyl, R0 from H to halogen, RX from H to cyano, and various R2 groups) to optimize the balance between selectivity and structural complexity. These parameter modifications allow tuning of molecular properties to achieve desired selectivity without excessive complexity
3Adaptability or versatility
If blood-brain barrier penetration is achieved, then brain tumor treatment capability is improved, but molecular size or polarity constraints increase
Solution Approach 1:
The patent applies parameter changes by selecting specific substituent combinations (such as C1-6 alkyl groups, halogen substitutions, and lipophilic R2 groups) that modify the compound's physicochemical parameters including logP, molecular weight, and polar surface area. These parameter optimizations enable blood-brain barrier penetration while maintaining PARP1 selectivity
Data Source
AI summary
A selective PARP1 inhibitor and an application thereof. Provided are a compound represented by general formula (I-A), and a stereoisomer, a pharmaceutically acceptable salt or a deuterated compound thereof. Also provided are a pharmaceutical composition comprising the compound or the stereoisomer thereof, and an application of the compound and the pharmaceutical composition in preparation of anti-tumor drugs.